The earnings call reflected strong operational execution and clinical progress for EyePoint, particularly with the rapid enrollment in pivotal trials and robust financial positioning. However, financial metrics showed a decline in revenue and increased losses due to higher operating costs, which balanced out the positive clinical achievements.

Company Guidance -

Q3 2025

During the EyePoint Second Quarter 2025 Financial Results and Recent Corporate Developments Conference Call, the company provided guidance emphasizing their significant progress in clinical trials and future financial outlook. The call highlighted the full enrollment of over 800 patients in the Phase III LUGANO and LUCIA trials for DURAVYU in wet-AMD, anticipating top-line data in mid-2026. EyePoint aims for a first-to-market advantage among sustained release therapies, supported by a robust clinical data package demonstrating a reduction in treatment burden by over 80% and non-inferior visual acuity compared to existing therapies. The company reported ending the second quarter with $256 million in cash and investments, projecting a cash runway into 2027, beyond the anticipated pivotal data readouts in 2026. Operating expenses increased to $67.6 million, driven by ongoing clinical trial costs. EyePoint also discussed expanding their cGMP manufacturing facility and maintaining a strong balance sheet as part of their commercialization strategy for DURAVYU.

Rapid Enrollment in Phase III Trials

EyePoint completed full enrollment in the Phase III LUGANO and LUCIA trials for DURAVYU in record time with over 800 patients, demonstrating strong execution and demand.

Financial Position and Cash Runway

EyePoint ended the second quarter with $256 million in cash and investments, with a cash runway extended into 2027, beyond pivotal data readouts for the wet-AMD program in 2026.

Positive Safety and Efficacy Data

DURAVYU demonstrated statistically non-inferior visual acuity compared to on-label aflibercept and reduced treatment burden by over 80% in Phase II trials.

Expansion and Commercial Readiness

EyePoint expanded its operations with a cGMP manufacturing facility in Massachusetts and has made significant strides in preparing for potential commercial success.

EyePoint Pharmaceuticals (EYPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EYPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.77 / -	-0.54	―	―	―
Aug 06, 2025	2025 (Q2)	-0.82 / -0.85	-0.58	-46.55% (-0.27)	―
May 07, 2025	2025 (Q1)	-0.67 / -0.65	-0.55	-18.18% (-0.10)	―
Mar 05, 2025	2024 (Q4)	-0.49 / -0.64	-0.33	-93.94% (-0.31)	―
Nov 07, 2024	2024 (Q3)	-0.55 / -0.54	-0.33	-63.64% (-0.21)	―	―
Aug 07, 2024	2024 (Q2)	-0.51 / -0.58	-0.61	4.92% (+0.03)	―	―
May 08, 2024	2024 (Q1)	-0.40 / -0.55	-0.56	1.79% (+0.01)	―	―
Mar 07, 2024	2023 (Q4)	-0.49 / -0.33	-1.16	71.55% (+0.83)	―
Nov 01, 2023	2023 (Q3)	-0.50 / -0.33	-0.49	32.65% (+0.16)	―
Aug 02, 2023	2023 (Q2)	1.38 / -0.61	-0.52	-17.31% (-0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EYPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$10.89	$10.58	-2.85%
May 07, 2025	$6.25	$6.09	-2.56%
Mar 05, 2025	$6.08	$6.58	+8.22%
Nov 07, 2024	$12.08	$11.59	-4.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Eyepoint Pharma (EYPT) report earnings?

Eyepoint Pharma (EYPT) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is Eyepoint Pharma (EYPT) earnings time?

Eyepoint Pharma (EYPT) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EYPT EPS forecast?

EYPT EPS forecast for the fiscal quarter 2025 (Q3) is -0.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing